- Home
- VERV
as 12-17-2024 4:00pm EST
Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 475.0M | IPO Year: | 2021 |
| Target Price: | $25.75 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.45 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.30 - $19.34 | Next Earning Date: | 11-05-2024 |
| Revenue: | $24,396,000 | Revenue Growth: | 219.91% |
| Revenue Growth (this year): | 97.47% | Revenue Growth (next year): | -36.01% |
Stock Insider Trading Activity of Verve Therapeutics Inc. (VERV)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Dorval Allison | VERV | Chief Financial Officer | Nov 29 '24 | Sell | $5.64 | 555 | $3,130.20 | 5,380 |
Latest Verve Therapeutics Inc. News
VERV Breaking Stock News: Dive into VERV Ticker-Specific Updates for Smart Investing
Simply Wall St.
a day ago
Verve Therapeutics Slides As Insider Purchases Lose Another US$65k
GlobeNewswire
19 days ago
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
a month ago
RBC Capital Adjusts Price Target on Verve Therapeutics to $17 From $20, Maintains Outperform, Speculative Risk Rating
Simply Wall St.
a month ago
Verve Therapeutics Third Quarter 2024 Earnings: Beats Expectations
Zacks
a month ago
Verve Therapeutics (VERV) Reports Q3 Loss, Tops Revenue Estimates
Associated Press Finance
a month ago
Verve Therapeutics: Q3 Earnings Snapshot
GlobeNewswire
a month ago
Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2024 Financial Results
GlobeNewswire
2 months ago
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Compare VERV vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VERV Verve Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.